• Огляд клінічних досліджень застосування дидрогестерона при звичному невиношуванні вагітності 
ua До змісту

Огляд клінічних досліджень застосування дидрогестерона при звичному невиношуванні вагітності 

HEALTH OF WOMAN.2015.4(100):80–86 
 

Огляд клінічних досліджень застосування дидрогестерона при звичному невиношуванні вагітності 
 

Carp Howard 
 

Література:

1. Salat-Baroux J. 1988. Recurrent spontaneous abortions. Reprod Nutr Dev 28:1555–68. http://dx.doi.org/10.1051/rnd:19881002; PMid:3073445

2. Hameed A, Malik S, Regan L. 2014. Should progestogen supplementation be used? No. In: Carp HJA, ed. Recurrent pregnancy loss, causes, controversies and treatment. 2nd ed. London: CRC Press:131–5.

3. Check J. 2014. Should progestogen supplementation be used? Yes. In: Carp HJA, ed. Recurrent pregnancy loss, causes, controversies and treatment. 2nd ed. London: CRC Press: 123–9.

4. Daya S. 1989. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A meta-analysis of controlled trials. Br J Obstet Gynaecol. 96:275–80. http://dx.doi.org/10.1111/j.1471-0528.1989.tb02386.x; PMid:2653415

5. Le Vine L. 1964. Habitual abortion. A controlled study of progestational therapy. West J Surg Obstet Gynecol. 72:30–6.

6. Swyer GIM, Daley D. 1953. Progesterone implantation in habitual abortion. Brit Med J. I:1073–7. http://dx.doi.org/10.1136/bmj.1.4819.1073

7. Goldzieher JW. 1964. Double-blind trial of a progestin in habitual abortion. JAMA 188:651–4. http://dx.doi.org/10.1001/jama.1964.03060330031008; PMid:14121287

8. Oates-Whitehead RM, Haas DM, Carrier JA. 2003. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 4:CD003511. http://dx.doi.org/10.1002/14651858.cd003511

9. El Zibdeh MY. 2005. Dydrogesterone in the reduction of recur- rent spontaneous abortion. J Steroid Biochem Mol Biol 97:431–4. http://dx.doi.org/10.1016/j.jsbmb.2005.08.007; PMid:16253504

10. Kumar A, Begum N, Prasad S et al. 2014. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil Steril. 102:1357–63. http://dx.doi.org/10.1016/j.fertnstert.2014.07.1251; PMid:25241364

11. Freedman RS. 1970. Progesterone defficiency in Pregnancy. S Afr Med J. 44:72–6.

12. Walch K, Hefler L, Nagele F. 2005. Oral dydrogesterone treatment during the first trimester of pregnancy: the prevention of miscarriage study (PROMIS). A double-blind, prospectively randomized, placebo- controlled, parallel group trial. J Matern Fetal Neonatal Med. 18:265–9. http://dx.doi.org/10.1080/14767050500246243; PMid:16318978

13. Szekeres-Bartho J, Barakonyi A, Polgar B et al. 1999. The role of gamma/ delta T cells in progesterone-mediated immunomodulation during pregnancy: a review. Am J Reprod Immunol. 42:44–8. http://dx.doi.org/10.1111/j.1600-0897.1999.tb00464.x; PMid:10429766

14. Raghupathy R, Makhseed M, Azizieh F et al. 2000. Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. Hum Reprod. 15:713–18. http://dx.doi.org/10.1093/humrep/15.3.713; PMid:10686225

15. Arck PC, Rьсke M, Rose M et al. 2008. Early risk factors for miscarriage: a prospective cohort study in pregnant women. Reprod Biomed Online 17:101–13. http://dx.doi.org/10.1016/S1472-6483(10)60300-8

16. Ghosh S, Chattopadhyay R, Goswami S et al. 2014. Assessment of sub- endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. J Obstet Gynaecol Res. 40:1871–6. http://dx.doi.org/10.1111/jog.12456; PMid:25056464

17. Stovall TG, Ling FW, Carson SA, Buster JE. 1992. Serum progesterone and uterine curettage in differential diagnosis of ectopic pregnancy. Fertil Steril. 57:456–7. PMid:1735503

18. Al-Sebai MA, Kingsland CR, Diver M et al. 1995. The role of a single progesterone measurement in the diagnosis of early pregnancy failure and the prognosis of fetal viability. Br J Obstet Gynaecol 102:364–9. http://dx.doi.org/10.1111/j.1471-0528.1995.tb11286.x; PMid:7612529

19. Chang IW. 1962. Clinical trial of isopregnenone, a new progestational agent. Med Ann Dist Colomb. 31:402–6.

20. Lopez Lopez E, Gonzales E, Noguera MC et al. 1988. Luteal phase defect and habitual abortion: therapy and results (article in Spanish). Acta Ginecol 14:72–5.

21. Aydar CK, Greenblatt RB. 1964. 6-dehydro-retroprogesterone (duphaston) an interesting progesterone-like compound. Int J Fertil. 9:585–95. PMid:14215356

22. Backer MH. 1962. Isopregnenone (Duphaston): a new progestational agent. Obstet Gynecol. 19:724–9. PMid:13863774

23. Gellй P, Schaeffer P, 1965. Apropos of the use of dydrogesterone in gynecology and obstetrics; clinical experience. Bull Fed Soc Gynecol Obstet Lang Fr.17:369–70. Article in French.

24. Jamain M, Grenet C. 1969. Utilisation de la 6-dй hydro-rйtroprogestйrone en obste мtrique. Indications, rйsultats. J Soc Nat De Gyn Obstet De: France 21:26–31. Article in French.

25. Sureau C, Combourieu P. 1964. Clinical study of 6-dehydro-retroproges- terone (dydrogesterone). Bull Fed Soc Gynecol Obstet Lang Fr. 16:263–9. Article in French. PMid:14204366

26. MacDonald RR, Goulden R, Oakey RE. 1972. Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstet Gynecol. 40:394–402. PMid:4560047

27. Balasch J, Creus M, Marquez M et al. 1986. The significance of luteal phase defficiency on fertility: a diagnostic and therapeutic approach. Hum Reprod. 1:145–7. PMid:3114310

28. Wahabi HA, Fayed AA, Esmaeil SA, Al Zeidan RA. 2011. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 12:CD005943. http://dx.doi.org/10.1002/14651858.cd005943.pub3

29. Carp HJA. 2012. A systematic review of dydrogesterone for the treat- ment of threatened miscarriage. Gynecol Endocrinol. 28:983–90. http://dx.doi.org/10.3109/09513590.2012.702875; PMid:22794306 PMCid:PMC3518297

30. Queisser-Luft A. 1997. Dydrogesterone use during pregnancy: over- view of birth defects reported since 1977. Early Hum Dev. 85:375–7. http://dx.doi.org/10.1016/j.earlhumdev.2008.12.016; PMid:19193503

31. Maconochie N, Doyle P, Prior S, Simmons R. 2007. Risk factors for first trimester miscarriage: results from a UK-population-based case– control study. BJOG 114:170–86. http://dx.doi.org/10.1111/j.1471-0528.2006.01193.x; PMid:17305901

32. Gracia CR, Sammel MD, Chittams J et al. 2005. Risk factors for spontaneous abortion in early symptomatic first-trimester pregnan- cies. Obstet Gynecol. 106:993–9. http://dx.doi.org/10.1097/01.AOG.0000183604.09922.e0; PMid:16260517

33. Achiron R, Tadmor O, Mashiach S. 1991. Heart rate as a predictor of first- trimester spontaneous abortion after ultrasound-proven viability. Obstet Gynecol. 78:330–4. PMid:1876359

34. Li TC, Makris M, Tomsu M et al. 2002. Recurrent miscarriage: aetiology, management and prognosis. Hum Reprod Update. 8:463–81. http://dx.doi.org/10.1093/humupd/8.5.463

35. Laufer MR, Ecker JL, Hill JA. 1994. Pregnancy outcome following ultrasound-detected fetal cardiac activity in women with a history of multiple spontaneous abortions. J Soc Gynecol Investig. 1:138–42. PMid:9419762

36. Abraham GE, Maroulis GB, Marshall JR. 1974. Evaluation of ovulation and corpus luteum function using measurements of plasma proges- terone. Obstet Gynecol. 44:522–5. PMid:4413313

37. la Marca A, Morgante G, De Leo V. 1998. Human chorionic gonadotropin, thyroid function, and immunological indices in threatened abortion. Obstet Gynecol. 92:206–11. http://dx.doi.org/10.1016/S0029-7844(98)00183-5

38. Florio P, Luisi S, D’Antona D et al. 2004. Maternal serum inhibin A levels may predict pregnancy outcome in women with threatened abortion. Fertil Steril. 81:468–70. http://dx.doi.org/10.1016/j.fertnstert.2003.08.008; PMid:14967395

39. Fiegler P, Katz M, Kaminski K, Rudol G. 2003. Clinical value of a single serum CA-125 level in women with symptoms of imminent abortion during the first trimester of pregnancy. J Reprod Med. 48:982–8. PMid:14738027

40. Schmidt T, Rein DT, Foth D et al. 2001. Prognostic value of repeated serum CA 125 measurements in first trimester pregnancy. Eur J Obstet Gynecol Reprod Biol. 97:168–73. http://dx.doi.org/10.1016/S0301-2115(00)00533-9